Cinolazepam
From Infogalactic: the planetary knowledge core
<templatestyles src="Module:Hatnote/styles.css"></templatestyles>
Systematic (IUPAC) name | |
---|---|
(RS)-3-[9-Chloro-6-(2-fluorophenyl)-4-hydroxy-3-oxo-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-2-yl]propanenitrile
|
|
Clinical data | |
Trade names | Gerodorm |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Legal status |
|
Routes of administration |
Oral |
Pharmacokinetic data | |
Bioavailability | 90–100% |
Metabolism | Hepatic |
Biological half-life | 9 hours[1] |
Excretion | Renal |
Identifiers | |
CAS Number | 75696-02-5 |
ATC code | N05CD13 (WHO) |
PubChem | CID: 3033621 |
DrugBank | DB01594 |
ChemSpider | 2298251 |
UNII | 68P0556B0U |
KEGG | D07328 |
ChEBI | CHEBI:59514 |
ChEMBL | CHEMBL2104926 |
Chemical data | |
Formula | C18H13ClFN3O2 |
Molecular mass | 357.8 |
|
|
|
|
(what is this?) (verify) |
Cinolazepam[2] (marketed under the brand name Gerodorm)[3] is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Due to its strong sedative properties, it is primarily used as an hypnotic.
Cinolazepam is not approved for sale in the United States or Canada.
See also
References
External links
<templatestyles src="Asbox/styles.css"></templatestyles>